LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

A Nanowire-based Liquid Biopsy Method for Detection of Tumors of the Central Nervous System

By LabMedica International staff writers
Posted on 30 Jun 2021
Print article
Image: Artist’s depiction of nanowire scaffolds for the screening of urinary microRNAs from patients with central nervous system tumors (Photo courtesy of Takao Yasui and Atsushi Natsume, Nagoya University)
Image: Artist’s depiction of nanowire scaffolds for the screening of urinary microRNAs from patients with central nervous system tumors (Photo courtesy of Takao Yasui and Atsushi Natsume, Nagoya University)
Researchers have developed a sterilizable nanowire-based device that can efficiently extract urinary microRNAs (miRNAs) and used it as the basis of a liquid biopsy method to detect tumors of the central nervous system (CNS).

MiRNAs comprise a class of about 20 nucleotides-long RNA fragments that block gene expression by attaching to molecules of messenger RNA in a fashion that prevents them from transmitting the protein synthesizing instructions they had received from the DNA. With their capacity to fine-tune protein expression via sequence-specific interactions, miRNAs help regulate cell maintenance and differentiation. In addition to miRNAs playing an essential role in tumor development, dysregulation of certain miRNAs has been associated with many different diseases, such as dementia and cardiovascular conditions.

Liquid biopsy methods to detect circulating nucleic acids from CNS tumors have not been developed due to the presence of the blood–brain barrier, which restricts molecular exchange between the tumor and the general circulation. Furthermore, collection of urinary biomarkers is difficult, and urine-based liquid biopsies have not been fully studied.

To solve these problems, investigators at Nagoya University (Japan) developed a mass-producible and sterilizable nanowire-based device capable of efficiently extracting urinary microRNAs. The device contained approximately 100 million zinc oxide nanowires and was suitable for actual medical use.

The investigators used the device as basis for a liquid biopsy method to analyze urinary microRNA expression profiles from 119 patients with CNS tumors and 100 control individuals. Results showed that this approach could distinguish the patients from control individuals at a sensitivity of 100% and a specificity of 97%, regardless of the malignancy and size of tumors.

"Urine can be collected easily without putting a burden on the human body," said senior author Dr. Atsushi Natsume, associate professor of neurosurgery at Nagoya University. "Urine-based liquid biopsy had not been fully investigated for patients with brain tumors, because none of the conventional methodologies can extract microRNAs from urine efficiently in terms of varieties and quantities. So, we decided to develop a device capable of doing it. In the future, by a combination of artificial intelligence and telemedicine, people will be able to know the presence of cancer, whereas doctors will be able to know the status of cancer patients just with a small amount of their daily urine."

The nanowire miRNA extraction device was described in the April 1, 2021, issue of the journal ACS Applied Materials & Interfaces.

Related Links:
Nagoya University

Gold Member
Serological Pipet Controller
PIPETBOY GENIUS
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Multi-Function Pipetting Platform
apricot PP5
New
Community-Acquired Pneumonia Test
RIDA UNITY CAP Bac

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The UV absorbance spectrometer being used to measure the absorbance spectra of cell culture samples (Photo courtesy of SMART CAMP)

Novel UV and Machine Learning-Aided Method Detects Microbial Contamination in Cell Cultures

Cell therapy holds great potential in treating diseases such as cancers, inflammatory conditions, and chronic degenerative disorders by manipulating or replacing cells to restore function or combat disease.... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.